InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week
October 26 2022 - 6:30AM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the research, development and
manufacturing of rare cannabinoids, announces it is supporting
initiatives to raise awareness of epidermolysis bullosa, a group of
rare genetic connective tissue disorders. Epidermolysis Bullosa
Global Awareness Week is October 25-31, 2022.
Alexandra Mancini, Senior Vice President of
Clinical and Regulatory Affairs for InMed commented, “In severe
cases of epidermolysis bullosa, or EB, the very fragile skin tears
easily and forms painful blisters and open wounds that do not heal
quickly. EB is a very important but rare disease that does not get
the attention it deserves. EB Awareness Week is an opportunity for
the community to come together to raise awareness about
epidermolysis bullosa to foster the necessary research and
resources to work towards better treatments and, eventually, a cure
to improve the lives of those with EB. InMed has undertaken a Phase
2 study in patients with EB in the hope that its cannabinol cream
will provide important symptom benefit.”
Throughout EB Awareness Week, InMed will be
raising awareness and supporting the EB community through education
and sharing personal EB stories via its social media channels. Help
InMed support EB patients, families and advocate organizations by
spreading awareness and following the work of important
organizations such as DEBRA of America, DEBRA Canada, DEBRA
International and EB Research Partnership.
What is epidermolysis
bullosa?Epidermolysis bullosa, or EB, is a group of rare
genetic skin diseases characterized by fragile skin that can lead
to extensive blistering and wounding. It affects skin and mucous
membranes, particularly of the gastrointestinal tract,
genitourinary and respiratory systems. It is a debilitating disease
affecting a small number of people, thus earning it an
orphan-disease status. The disease has no definitive cure and all
currently approved treatments are directed towards symptom relief.
Learn more:
https://www.inmedpharma.com/learn/what-is-epidermolysis-bullosa/.
Learn more about InMed’s INM-755 EB study:
https://www.inmedpharma.com/pharmaceutical/inm-755-for-epidermolysis-bullosa/
About InMed: InMed
Pharmaceuticals is a global leader in the pharmaceutical research,
development and manufacturing of rare cannabinoids and cannabinoid
analogs, including clinical and preclinical programs targeting
the treatment of diseases with high unmet medical needs. We also
have significant know-how in developing proprietary manufacturing
approaches to produce cannabinoids for various market sectors. For
more information, visit www.inmedpharma.com.
Investor Contact: Colin ClancyVice President,
Investor Relations & Corporate CommunicationsT:
+1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: undertaking a Phase 2 study in patients
with EB in the hope that its cannabinol cream will provide
important symptom benefit; being a global leader in the research,
development, manufacturing and commercialization of rare
cannabinoids; and delivering new treatment alternatives to patients
that may benefit from cannabinoid-based pharmaceutical drugs.
With respect to the forward-looking information
contained in this news release, InMed has made numerous assumptions
regarding, among other things: the ability to obtain all necessary
regulatory approvals on a timely basis, or at all; and continued
economic and market stability. While InMed considers these
assumptions to be reasonable, these assumptions are inherently
subject to significant business, economic, competitive, market and
social uncertainties and contingencies. Additionally, there are
known and unknown risk factors which could cause InMed's actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking information contained herein. A
complete discussion of the risks and uncertainties facing InMed’s
stand-alone business is disclosed in InMed’s Annual Report on Form
10-K and other filings with the Security and Exchange Commission on
www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Jun 2024 to Jul 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Jul 2023 to Jul 2024